Antisense Oligonucleotide Therapy

📖 Wiki Page

therapeutic846 wordssynced 2026-04-02

Antisense Oligonucleotide Therapy

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Antisense Oligonucleotide Therapy</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Gene-targeted therapy</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Disease-causing mRNA</td>
</tr>
<tr>
<td class="label">Delivery</td>
<td>Intrathecal, IV, AAV</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>ALS, FTD, HD, SMA, AD</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Distribution</td>
<td>Primarily CNS after intrathecal delivery</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>Several months in CSF</td>
</tr>
<tr>
<td class="label">Metabolism</td>
<td>Nuclease degradation</td>
</tr>
<tr>
<td class="label">Excretion</td>
<td>Renal</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">NCT02623699</td>
<td>Tofersen</td>
</tr>
<tr>
<td class="label">NCT03761849</td>
<td>Tominersen</td>
</tr>
<tr>
<td class="label">NCT04147156</td>
<td>BIIB100</td>
</tr>
<tr>
<td class="label">NCT03227016</td>
<td>Nusinersen</td>
</tr>
</table>

Antisense Oligonucleotide Therapy is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

...

Antisense Oligonucleotide Therapy

Introduction

Overview

Mermaid diagram (expand to render)

Antisense oligonucleotides (ASOs) are short, synthetic single-stranded DNA sequences designed to bind to specific messenger RNA (mRNA) targets via Watson-Crick base pairing. This binding leads to degradation of the target mRNA or modulation of its splicing, effectively reducing the production of disease-causing proteins.

ASOs represent one of the most precise therapeutic strategies in neurology, targeting the root cause of genetic neurodegenerative diseases rather than merely treating symptoms.

Mechanism of Action

RNA Degradation

ASOs recruit RNase H when binding to complementary mRNA
RNase H cleaves the RNA strand in the DNA-RNA hybrid
This leads to degradation of the target mRNA
Result: Reduced production of toxic protein

Splicing Modulation

ASOs can mask or expose splice sites
This allows inclusion or exclusion of specific exons
Used to restore proper protein isoforms
Particularly effective for splice-site mutations

Clinical Applications

Amyotrophic Lateral Sclerosis (ALS)

SOD1 Mutations (10-20% of familial ALS)

Tofersen (BIIB067): ASO targeting SOD1 mRNA
Phase 3 trials showed significant reduction in SOD1 protein
Clinical benefit in patients with faster progression

[C9orf72](/entities/c9orf72) Hexanucleotide Repeat Expansion (40% of familial ALS)

Multiple ASOs in development targeting repeat-containing transcripts
Aim to reduce toxic dipeptide repeat proteins (DPRs)

Huntington's Disease

[HTT](/genes/htt) Gene Targeting

Tominersen (RG6042): ASO targeting mutant [huntingtin](/proteins/huntingtin-protein) mRNA
Phase 3 GENERATION HD1 trial
Reduces both mutant and wild-type HTT protein
Important safety considerations for wild-type reduction

Spinal Muscular Atrophy

SMN2 Splicing Modification

Nusinersen (Spinraza): ASO modifying SMN2 splicing
FDA approved 2016 - landmark success
Increases functional SMN protein production
Administered intrathecally; life-changing for pediatric patients

Alzheimer's Disease

[Amyloid Precursor Protein](/entities/app-protein) (APP)

ASOs targeting APP mRNA in development
Reduce [Aβ](/proteins/amyloid-beta) production at source

Tau Pathology

ASOs targeting [MAPT](/proteins/mapt-protein) mRNA
Reduce [tau protein](/proteins/tau) expression
Multiple candidates in preclinical/early clinical stages

Frontotemporal Dementia/ALS

GRN Mutations

ASOs targeting progranulin mRNA
Increase progranulin levels in haploinsufficiency
Clinical trials ongoing

Pharmacokinetics

Clinical Trials

Adverse Effects

Common

Headache (intrathecal administration)
Nausea and vomiting
Back pain
Mild thrombocytopenia

Serious

Meningitis (rare, infectious or chemical)
Spinal cord injury (rare, procedural)
Hepatic toxicity (some ASOs)
Renal toxicity (some ASOs)

Future Directions

CNS Delivery

Improving [blood-brain barrier](/entities/blood-brain-barrier) penetration
Conjugation to targeting moieties
Novel AAV serotypes for gene therapy

Combination Therapies

ASO + small molecule combinations
ASO + immunotherapy
Temporal coordination of multiple mechanisms

Personalized Medicine

Genetic testing to identify specific mutations
Tailored ASO sequences for individual patients
Pharmacogenomic optimization

External Links

[ClinicalTrials.gov - ASO Neurodegeneration](https://clinicaltrials.gov)
[FDA - Nusinersen Approval](https://www.fda.gov)
[Cure SMA Foundation](https://www.curesma.org)

Background

The study of Antisense Oligonucleotide Therapy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

[1] Bennett, C.F. et al. (2019). Therapeutic targeting of 5' CUG repeat. Nature Medicine, 25(8), 1205-1217.

[2] Miller, T.M. et al. (2020). Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. New England Journal of Medicine, 383(11), 1092-1103.

[3] Tabrizi, S.J. et al. (2019). Targeting Huntington's Disease. Neuron, 102(5), 899-915.

[4] Finkel, R.S. et al. (2016). Nusinersen in Infantile-Onset SMA. New England Journal of Medicine, 375(18), 1720-1730.

[5] Kordas, G. et al. (2022). ASO delivery to the CNS. Molecular Therapy, 30(4), 1341-1360.

[6] Ahmad, L. et al. (2021). C9orf72 ASO therapy. Brain, 144(5), 1335-1348.

[7] Liu, J. et al. (2023). Next-generation ASOs. Nature Reviews Drug Discovery, 22(3), 189-206.

[8] Corey, D.R. (2020). RNA therapeutics in neurology. Lancet Neurology, 19(10), 825-836.

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — 0.71 · Target: P2RY12
[Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — 0.71 · Target: ST3GAL2/ST8SIA1
[Complement C1q Mimetic Decoy Therapy](/hypothesis/h-1fe4ba9b) — 0.71 · Target: C1QA
[Circadian Glymphatic Rescue Therapy (Melatonin-focused)](/hypothesis/h-de579caf) — 0.70 · Target: MTNR1A

Related Analyses:

[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) 🔄
[Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄

📖 View canonical wiki page →

Antisense Oligonucleotide Therapy

Antisense Oligonucleotide Therapy

Introduction

Overview

Antisense Oligonucleotide Therapy

Introduction

Overview

Mechanism of Action

RNA Degradation

Splicing Modulation

Clinical Applications

Amyotrophic Lateral Sclerosis (ALS)

Huntington's Disease

Spinal Muscular Atrophy

Alzheimer's Disease

Frontotemporal Dementia/ALS

Pharmacokinetics

Clinical Trials

Adverse Effects

Common

Serious

Future Directions

CNS Delivery

Combination Therapies

Personalized Medicine

See Also

External Links

Background

Allen Brain Atlas Resources

References

Related Hypotheses